Today: 9 June 2026
Microsoft (MSFT) stock snaps back above $399 after Stifel downgrade, AI spend in focus
6 February 2026
2 mins read

Microsoft (MSFT) stock snaps back above $399 after Stifel downgrade, AI spend in focus

New York, February 6, 2026, 16:03 (ET) — Into after-hours trading

  • MSFT clawed back roughly 1.5% Friday after tumbling 5% the day before.
  • Stifel’s unusual downgrade sharpened the spotlight on Azure’s ongoing capacity constraints and mounting AI expenses.
  • Investors are eyeing those mounting AI infrastructure costs at Big Tech, questioning if ballooning bills will squeeze margins before any revenue gains show up.

Microsoft (MSFT.O) finished Friday’s session up 1.5% at $399.45, recovering part of Thursday’s steep drop. Shares bounced between $392.92 and $401.31 throughout the day.

Investors are rethinking the pace of the AI-driven capital spending wave and questioning just when the payoff lands. Microsoft slid 5% Thursday. Alphabet (GOOGL.O) put as much as $185 billion in 2026 spending on the table, putting the focus squarely back on the return side of the ledger. “We’re seeing this volatility about whether this investment will translate… into results,” said Tom Hainlin, investment strategist at U.S. Bank Wealth Management. Reuters

Amazon.com (AMZN.O) ratcheted up the stakes on Friday, revealing plans for a $200 billion capital spend in 2026. Tech heavyweights in the U.S. are now targeting a collective investment north of $630 billion for data centers and AI chips. “The magnitude of the spend is materially greater than consensus expected,” analysts at MoffettNathanson said, adding a caution: “the margin of error is shrinking.” Reuters

It’s not just the bill drawing concern. Software and data stocks are under pressure, with investors worried that new AI products could sap demand—a concern Reuters noted was partly sparked by Anthropic’s latest Claude plug-in. “It got too pricey,” said Andrew Wells, chief investment officer at SanJac Alpha. Carlota Estragues Lopez, a strategist at St. James’s Place, added that investors are reading the headlines “far more cautiously.” Reuters

Microsoft caught some flak Thursday after Stifel slashed its rating on the tech giant to Hold from Buy and chopped the price target to $392 from $540. Analyst Brad Reback said it was “time for a break” and described projections for 2027 as “too optimistic.” Reback flagged Azure’s supply issues along with mounting AI rivalry. Stifel also pushed its estimate for Microsoft’s fiscal 2027 capital spending up to roughly $200 billion. Investing.com UK

U.S. tech shares snapped back Friday, lifted by a surge in chipmaker names after a bruising stretch. “The market looks like it was getting a bit overdone to the downside,” said Robert Pavlik, senior portfolio manager at Dakota Wealth. Reuters

Microsoft’s quarterly results, out in late January, showed revenue up 17% to $81.3 billion for the period ending Dec. 31. Azure and the rest of its cloud services jumped 39%. “Microsoft Cloud revenue crossed $50 billion this quarter,” CFO Amy Hood noted. Microsoft

The core issue still stands—investors are after firmer evidence that all this spending translates to lasting profit instead of simply stacking up more servers. A hiccup in cloud growth, or another round of surprise spending, could wipe out any relief rally in a hurry.

Microsoft’s fiscal Q3 numbers drop April 29, per Yahoo Finance’s earnings calendar. Investors are keyed in on updates around spending, capacity, and how fast AI products actually start to show up in revenue.

Stock Market Today

  • U.S. Inflation Poised to Exceed 4% for First Time Since 2023, Pressures Mount on Fed
    June 9, 2026, 10:06 AM EDT. U.S. inflation is set to surpass 4% for the first time since 2023, signaling rising consumer prices and intensifying economic pressures. This uptick, measured by the year-over-year increase in the Consumer Price Index (CPI), highlights renewed challenges for the Federal Reserve (Fed) as it grapples with balancing inflation control against economic growth. The rise in inflation may influence the Fed's monetary policy decisions amid concerns over sustained price increases impacting households and businesses for the remainder of the year.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
Confluent stock edges higher as IBM deal vote nears after fresh merger filing
Previous Story

Confluent stock edges higher as IBM deal vote nears after fresh merger filing

Oracle stock rebounds after a bruising week — what traders are watching next for ORCL
Next Story

Oracle stock rebounds after a bruising week — what traders are watching next for ORCL

Go toTop